Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers
Information source: University Hospital, Grenoble
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: treprostinil (Drug); iloprost (Drug); NaCl 0.9% (Drug)
Phase: Phase 1/Phase 2
Status: Completed
Sponsored by: University Hospital, Grenoble
Summary
The purpose of this study is to test whether prostacyclin analogues' cathodal iontophoresis
induce a cutaneous vasodilation in healthy volunteers's forearm, without local side effects.
Clinical Details
Official title: Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Amplitude of forearm cutaneous vasodilatation assessed using laser Doppler imaging
Secondary outcome: Local tolerance assessed clinically
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- healthy volunteers
- age above 18
Exclusion Criteria:
- any chronic disease
- any drug intake
Locations and Contacts
Unité de Pharmacologie Clinique, Inserm CIC3, CHU Grenoble, Grenoble 38043, France
Additional Information
Starting date: January 2010
Last updated: October 5, 2011
|
